IONIQ Sciences is awarded “Best of Salt Lake City – Cancer Testing 2021”
Salt Lake City, UT, December 21, 2021 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”) is honored to announce it has been awarded “Best of Salt Lake City – Cancer Testing 2021.” We are humbled to have our mission to modernize early-stage cancer detection continue to be recognized nationally and locally. Through our novel application of bioimpedance technology, we believe that we’re measuring the body’s systemic response to cancer in the earliest and most-treatable stages of the disease. Our first planned product will be our IONIQ ProLung Test, which has already been designated a ‘Breakthrough Device’ by the FDA. Just this month our feasibility results on breast cancer were published in the IEEE Access peer-reviewed journal, which is tracking to be our second product.
About IONIQ Sciences, Inc.
IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics (EIA) or bioimpedance technology and Artificial Intelligence (AI). IONIQ Science’s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA.
For further information about IONIQ Sciences, Inc., please contact:
Andy Robertson | 1-801-736-0729 | acr@IONIQsciences.com
IONIQ Sciences, Vice President of Business Development
IONIQ Sciences, Inc.
350 W. 800 N., Suite 214
Salt Lake City, Utah 84103